Stand out for this role — generate a tailored resume and cover letter in about a minute.
Centessa Pharmaceuticals, a Boston-based company, is seeking a Senior Director of Analytical Development to lead phase-appropriate analytical strategy across CDMOs for drug substance and product development. You will drive method development, qualification, and stability programs for small molecules, ensuring cGMP compliance and timely regulatory submissions.
The role requires 10+ years in small molecule analytical development, a PhD preferred, and strong leadership across cross-functional
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. Centessa’s lead investigational candidate – cleminorexton (formerly ORX750) – is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Centessa's OX2R agonist portfolio includes additional clinical and preclinical-stage assets with potential utility across a broader range of neurological, neurodegenerative, and neuropsychiatric conditions.
Headquartered in Boston, Massachusetts, Centessa was recognized as a Great Place to Work® in 2026.
Centessa’sCMC groupis seekingaSenior Director of AnalyticalDevelopmentwithin the CMC group. The successful candidate will have hands‑on experience in the development and validation of raw material, in‑process, small molecule drug substance, and solid oral dose drug product methods at all stages of development.
Reporting to the Executive Director, this rolewill drive analytical method gap assessments, method development, and strategy at various CDMOs and liaise cross‑functionally with drug substance and drug product teams across programs. Comprehensive working knowledge of cGMP and Regulatory guidance as they relate to regulatory starting material, drug substance and drug product development, characterization, release, and stability testing of small molecules is paramount.
This position will be accountable for all analytical CMC data from external CDMOs to meet company deliverables and timelines. Travel to vendors both domestically and internationally will be required.
The annual base salary range for the Sr. Director level position is $165,000.00 to $250,000.00. Individual compensation within this range will be determined based on a variety of factors, including qualifications, skills, relevant experience, job knowledge and location.
In addition to base pay, this role is eligible for a discretionary annual bonus. The Company also offers a comprehensive benefits package, which includes a 401(k) plan, company‑sponsored medical, dental, vision, and life insurance, generous paid time off, and a health and wellness program.
The (Senior) Director, Analytical Development role is a based in the US, with occasional travel.
Full-Time, Exempt
Centessa Pharmaceuticals, a wholly owned subdisary of Eli Lilly and Company believes in a diverse environment and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion, or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. We will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Please note: We will not assign referral rights for any unsolicited resumes from recruitment agencies.